Last 12 months
- July 2025 (2)
- June 2025 (3)
- May 2025 (8)
- April 2025 (2)
- March 2025 (5)
- February 2025 (4)
- January 2025 (2)
- December 2024 (4)
- November 2024 (1)
- October 2024 (5)
- September 2024 (6)
- August 2024 (2)
- Show All
Tags
- Infection (1)
- Special Interest Groups (4)
- Immunology & Cell Biology (25)
- Women's Initiative (10)
- ASI Awards (97)
- Clinical & Translational Immunology (9)
- ASI (114)
- Day of Immunology (19)
- Competition (11)
- ASI Membership (30)
- Visiting Speaker Program (4)
- Immunology (113)
- Closing Soon (5)
- Journals (20)
- Vaccines (32)
- Event/Meeting (58)
- Equity, Diversity, Inclusion (1)
- Show All
Latest News
Wednesday January 13, 2021
ASI Media Release
13th Jan 2021. Amended.
Clarification by The Australian and New Zealand Society for Immunology in response to comments published in The Age and the SMH on 13th Jan 2021.
In response to articles published in The Age and The SMH on the 13th Jan 2021, the Australian and New Zealand Society for Immunology (ASI) would like to expand on comments attributed to Professor Stephen Turner and ASI. Regarding a pause on the rollout of the Oxford-AstraZeneca Vaccine, the President of ASI, Professor Stephen Turner was speaking as an expert in immunology and vaccine responses. The intention was to highlight that the Oxford-AstraZeneca vaccine has a beneficial role to play in what is a multi-pronged approach to combatting the impact of the COVID19 pandemic.
The current position is that ASI does not advocate a pause on the rollout of the Oxford-AstraZeneca Vaccine.
Data shows that the Oxford-AstraZeneca vaccine is a robust and safe vaccine that has between 62% - 90% efficacy against SARS-CoV-2.
Prof. Stephen Turner, ASI President
Prof. John Fraser, ASI Past President
Dr. Connie Jackaman, ASI Hon. Secretary
Dr. Asolina Braun, ASI Treasurer
Dr. Tyani Chan, ASI General Manager
